Patterns of brachyury expression in chordomas.

[1]  F. Barral,et al.  Chordomas: A review with emphasis on their pathophysiology, pathology, molecular biology, and genetics. , 2020, Pathology, research and practice.

[2]  M. Selig,et al.  Dedifferentiated Chordoma , 2020, The American journal of surgical pathology.

[3]  D. Gravel,et al.  Chordoma of the Head and Neck: A Review , 2018, Head and Neck Pathology.

[4]  A. D. Dei Tos,et al.  Extra-axial chordoma: a clinicopathologic analysis of six cases , 2018, Virchows Archiv.

[5]  G. Nielsen,et al.  Clinicopathologic characteristics of poorly differentiated chordoma , 2018, Modern Pathology.

[6]  Y. Temel,et al.  Notochord isolation using laser capture microdissection , 2017, Journal of Chemical Neuroanatomy.

[7]  S. Gui,et al.  Clinical Features and Prognostic Factors of Children and Adolescents with Clival Chordomas. , 2017, World neurosurgery.

[8]  J. Schlom,et al.  Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases , 2015, The American journal of surgical pathology.

[9]  Liwei Zhang,et al.  Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas , 2015, Molecular medicine reports.

[10]  J. Schlom,et al.  Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody , 2014, Oncotarget.

[11]  Hui-lin Yang,et al.  Histological Study of Chordoma Origin From Fetal Notochordal Cell Rests , 2013, Spine.

[12]  H. Mankin,et al.  Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma , 2013, PloS one.

[13]  T. Kawase,et al.  Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis. , 2013, Journal of neuropathology and experimental neurology.

[14]  S. Weiss,et al.  Soft Tissue Chordomas: A Clinicopathologic Analysis of 11 Cases , 2013, The American journal of surgical pathology.

[15]  F. Guadagni,et al.  Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer , 2012, Clinical Cancer Research.

[16]  Z. Gokaslan,et al.  Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. , 2011, Journal of neurosurgery.

[17]  J. Brooks,et al.  Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases , 2011, Modern Pathology.

[18]  T. Jacques,et al.  Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional‐based study , 2011, The Journal of pathology.

[19]  R. Dikshit,et al.  Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases. , 2010, Archives of pathology & laboratory medicine.

[20]  Andrew H. Beck,et al.  Distinguishing Chordoid Meningiomas From Their Histologic Mimics: An Immunohistochemical Evaluation , 2009, The American journal of surgical pathology.

[21]  R. Seethala,et al.  Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis , 2008, Modern Pathology.

[22]  M. D. den Bakker,et al.  Brachyury Expression in Extra-axial Skeletal and Soft Tissue Chordomas: A Marker that Distinguishes Chordoma From Mixed Tumor/Myoepithelioma/Parachordoma in Soft Tissue , 2008, The American journal of surgical pathology.

[23]  J. Schlom,et al.  The Human T-Box Mesodermal Transcription Factor Brachyury Is a Candidate Target for T-Cell–Mediated Cancer Immunotherapy , 2007, Clinical Cancer Research.

[24]  S. Henderson,et al.  Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas , 2006, The Journal of pathology.

[25]  Neil Sebire,et al.  A molecular map of mesenchymal tumors , 2005, Genome Biology.

[26]  F. Giangaspero,et al.  SMARCB1/INI1 Involvement in Pediatric Chordoma: A Mutational and Immunohistochemical Analysis , 2017, The American journal of surgical pathology.